Xpert MTB/RIF Use Is Associated With Earlier Treatment Initiation and Culture Conversion Among Patients With Sputum Smear-Negative Multidrug-Resistant Tuberculosis.

Kipiani, Maia; Graciaa, Daniel S; Buziashvili, Mariana; Darchia, Lasha; Avaliani, Zaza; Tabagari, Nino; Mirtskhulava, Veriko; Kempker, Russell R

Kipiani, Maia; Graciaa, Daniel S; Buziashvili, Mariana; Darchia, Lasha; Avaliani, Zaza; Tabagari, Nino; Mirtskhulava, Veriko; Kempker, Russell R.

Afiliación

Kipiani M; National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
Graciaa DS; The University of Georgia, Tbilisi, Georgia.
Buziashvili M; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Darchia L; National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
Avaliani Z; Georgian Healthcare Group, Tbilisi, Georgia.
Tabagari N; National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
Mirtskhulava V; David Tvildiani Medical University, Tbilisi, Georgia.
Kempker RR; KNCV Tuberculosis Foundation, The Hague, the Netherlands.

Open Forum Infect Dis ; 8(12): ofab551, 2021 Dec.

Article en En | MEDLINE | ID: mdl-34877367

Palabras clave

Xpert MTB/RIF; culture conversion; drug-resistant TB; molecular diagnostics

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Open Forum Infect Dis Año: 2021 Tipo del documento: Article País de afiliación: Georgia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google